Dellon ES, Peterson KA, Murray JA, et al. - Given the effectiveness of AK002 (lirentelimab), an anti–Siglec-8 antibody, in depleting eosinophils and inhibiting mast cells and its observed potential as a treatment for eosinophilic gastritis and duodenitis in animal models, researchers conducted this phase 2 trial randomly assigning 65 patients with symptomatic eosinophilic gastritis, eosinophilic duodenitis, or both conditions in a 1:1:1 ratio to receive 4 monthly infusions of low-dose AK002, high-dose AK002, or placebo. Per findings, AK002 resulted in reduction of gastrointestinal eosinophils and symptoms in patients with eosinophilic gastritis or duodenitis. They indicated more common infusion-related reactions with AK002 than with placebo.